Contribution to the Global Fund to Fight AIDS, Tuberculosis and Malaria (GF)


Health is a precondition, an indicator and a result of sustainable development. The Global Fund (GF) follows the vision of a world free of HIV/AIDS, tuberculosis and malaria. It collects and channels a big share of the international funds dedicated to end these epidemics that disproportionately affect the poorest and most vulnerable people. Its support to country programmes has saved 27 million lives since 2002. In the coming years, the challenge is to maintain this progress and step up the fight to ending the epidemics. 

Pays/région Thème Période Budget
Monde entier
Santé
Maladies sexuellement transmissibles (y compris VIH/sida)
Paludisme
Renforcement des systèmes de santé
01.01.2020 - 31.12.2022
CHF 64'000'500
Domaine de compétences

The GF is a 21st-century partnership organization - including the private sector and civil society in decision-making - based in Geneva. It is designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics.

 

Its mission is to attract, leverage and invest additional ressources to end these epidemics and to support achievement of the Sustainable Development Goals. Foremost a financing mechanism, the GF works in complementarity with UN-organisations and other entities that develop disease-specific strategies, under-stand the country contexts and needs and that support countries in implementing their national health strategies with GF funds.

It is one of the international organisations channeling the majority of international funds for the area of malaria, TB and HIV/AIDS especially to low income countries where these diseases affect many people.

Since March 2019, the Global Fund is the main tenant of the Global Health Campus, a building that hosts five international health organizations, thus becoming a landmark that reinforces Geneva's role as the international health capital.

Priorités stratégiques de la Suisse et de l'organisation et leur cohérence

Switzerland depends on international partners such as The Global Fund to fight epidemics with global reach. This is why it is defined as a priority multilateral organisation in the Dispatch on Switzerland’s International cooperation 2017-2020.

This strategic partnership which includes Swiss research entities and Swiss companies, is in the Swiss interest. Funds granted to countries by the GF are used for example to purchase quality medicines at affordable prices, insectice-treated mosquito nets, and other products to fight the three diseases.

The Global Fund’s strategic orientation is in line with the Swiss Health Foreign Policy and SDC’s health policies. Furthermore, it also invests in supporting the role of civil society and the provision of treatment and health services for vulnerable or marginalized populations (ex: key populations, women and girls), both important issues for Switzerland.

Switzerland’s priorities correspond to areas where the GF can further improve its efficiency and effectiveness according to independent evaluators: evidence-based results measurement in health systems performance and “country coordinating mechanisms”. The latter are entities at country level that coordinate action among national stakeholders and the use of GF funds in an inclusive manner (government, civil society, private sector, international donors).

Résultats de l'engagement déployé à ce jour par l'organisation

Since it was created in 2002, the Global Fund has contributed to the fight against the three diseases as part of a collective effort that includes strong contributions by governments, civil society, the private sector and people affected by HIV/AIDS, TB and malaria.

Thanks to its active communication of collective results, the GF manages to raise large amounts of multilateral funding and invests nearly US$4 billion a year to support programmes run by partners with local expertise in countries and communities most in need.

  • 27 million lives saved; through health programs supported by the GF partnership by the end of 2017
  • A decline of one-third in the number of people dying from HIV, TB and malaria since 2002
  • During 2017:
  • 17.5 million people on antiretroviral treatment for HIV
  • 5 million people with TB treated
  • 197 million mosquito nets distributed through malaria programs
Résultats de l'engagement déployé à ce jour par la Suisse

Switzerland has contributed to guaranteeing that the GF’s work on HIV/AIDS and malaria is aligned to global norms and standards and that it evolves to respond to the needs of the poorest and most vulnerable people.

Switzerland’s engagement on the role of Country coordinating mechanisms has resulted in approval by the Board to fund an initiative to strengthen them. Switzerland’s partnership with Germany on BACKUP Health (GIZ) contributed to bringing forward this strategic discussion thanks to technical assistance to GF country partners.

As part of the Ethics and Governance Committee Switzerland has contributed strongly to further developing these functions at the GF.

Switzerland’s financial contribution is reinforced by its bilateral work on health systems, malaria and HIV/AIDS in partner countries that it has in common with the GF.

Effets directs de l'engagement actuel de l'organisation

The health goals and targets set in the 2017-2022 Global Fund Strategy are explictly linked to the global disease targets developed by its main multilateral specialised partners in the fight against HIV/AIDS, TB and malaria epidemics. The Global Fund will also contribute to the realization of the Sustainable Development Goals adopted by all Member States of the United Nations in September 2015. In particular financing provided through the Global Fund will contribute to enable countries meet Goal 3 and the associated target 3.3 that seeks to end the epidemics of HIV/AIDS, TB, and malaria by 2030.

  • The objectives of the strategy 2017-2020 are:
  • Maximise impact against HIV, TB and Malaria
  • Bulid Resilient and Sustainable Systems for Health
  • Promote and Protect Human Rights and Gender Equality
  • Mobilize Increased Resources.
  • Despite progress, emerging new threats have pushed global efforts off-track regarding the epidemics. To return to the path of ending the epidemics, halving mortality rates from the three diseases and building stronger health systems, the Global Fund aims to raise US$14 billion for the sixth replenishment of resources covering the period 2020 to 2022.
Effets directs de l'engagement actuel de la Suisse
  • Contribute to the fight against HIV/AIDS and malaria epidemics by leveraging Swiss expertise and ensuring that interventions supported by the GF are aligned with those of other global and national health actors.
  • Strengthen coordination platforms in countries where the different national health actors, including civil society, define the needs for funding requests according to national priorities.
  • Support the GF’s efforts to intensify its contribution to health systems strengthening to ensure sustainability of results
  • Commit to progress on institutional issues such as risk management, good governance and ethical behaviour.
  • Switzerland currently occupies the “Alternate Board Member” seat within the Canada-Switzerland-Australia constituency at the GF board.
Direction/office fédéral responsable DDC
Crédit Coopération au développement
Partenaire de projet Partenaire contractuel
Autre organisation internationale
  • Fonds global pour la lutte contre le SIDA, la tuberculose et la malaria


Budget Phase en cours Budget de la Suisse CHF   64'000'500 Budget suisse déjà attribué CHF   18'500'000 Budget de l'Organisation CHF   14'000'000'000
Donateur d'ordre

15th rank (among donor countries)

Donateurs

2017-2019 Replenishment: a) Government donors: US, UK, France, Germany, Japan, Canada, European Commission, Sweden, Norway, The Netherlands, Australia, Italy, Switzerland (13th); b) Private sector and nongovernmental donors: USD ≈ 895 million

Coordination avec autres projets et acteurs

In the Global Fund Board, Switzerland belongs to a constituency with Canada and Australia. Canada is the Board member, and Australia and Switzerland rotate for the alternate member seat. Switzerland is currently alternate board member until mid-2020.

Phases du projet Phase 13 01.01.2020 - 31.12.2022   (Phase en cours) Phase 12 01.01.2017 - 31.12.2019   (Completed) Phase 11 01.01.2014 - 31.12.2016   (Completed)